Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Let us not underestimate the long-term risk of SPLC after surgical resection of NSCLC.
Leroy T, Monnet E, Guerzider S, Jacoulet P, De Bari B, Falcoz PE, Gainet-Brun M, Lahourcade J, Alfreijat F, Almotlak H, Adotevi O, Pernet D, Polio JC, Desmarets M, Woronoff AS, Westeel V. Leroy T, et al. Among authors: almotlak h. Lung Cancer. 2019 Nov;137:23-30. doi: 10.1016/j.lungcan.2019.09.001. Epub 2019 Sep 3. Lung Cancer. 2019. PMID: 31521979
Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice.
Mouillet G, Falcoz A, Fritzsch J, Almotlak H, Jacoulet P, Pivot X, Villanueva C, Mansi L, Kim S, Curtit E, Meneveau N, Adotevi O, Jary M, Eberst G, Vienot A, Calcagno F, Pozet A, Djoumakh O, Borg C, Westeel V, Anota A, Paget-Bailly S. Mouillet G, et al. Among authors: almotlak h. Qual Life Res. 2021 Nov;30(11):3255-3266. doi: 10.1007/s11136-020-02721-0. Epub 2021 Jan 2. Qual Life Res. 2021. PMID: 33387291
Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.
Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U, Bouard A, Kim S, Klajer E, Jary M, Meynard G, Vienot A, Nardin C, Bazan F, Lepiller Q, Westeel V, Adotévi O, Borg C, Kroemer M. Mansi L, et al. Among authors: almotlak h. Eur J Cancer. 2021 Jun;150:1-9. doi: 10.1016/j.ejca.2021.03.033. Epub 2021 Mar 26. Eur J Cancer. 2021. PMID: 33882374 Free PMC article. Clinical Trial.
Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer.
Eberst G, Vernerey D, Laheurte C, Meurisse A, Kaulek V, Cuche L, Jacoulet P, Almotlak H, Lahourcade J, Gainet-Brun M, Fabre E, Le Pimpec-Barthes F, Adotevi O, Westeel V. Eberst G, et al. Among authors: almotlak h. BMC Cancer. 2022 May 11;22(1):529. doi: 10.1186/s12885-022-09628-8. BMC Cancer. 2022. PMID: 35546670 Free PMC article.
Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
Adotévi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V. Adotévi O, et al. Among authors: almotlak h. J Clin Oncol. 2023 Jan 10;41(2):373-384. doi: 10.1200/JCO.22.00096. Epub 2022 Sep 7. J Clin Oncol. 2023. PMID: 36070539 Clinical Trial.
Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.
Mouillet G, Paillard MJ, Maurina T, Vernerey D, Nguyen Tan Hon T, Almotlak H, Stein U, Calcagno F, Berthod D, Robert E, Meurisse A, Thiery-Vuillemin A. Mouillet G, et al. Among authors: almotlak h. Trials. 2018 Apr 12;19(1):221. doi: 10.1186/s13063-018-2613-8. Trials. 2018. PMID: 29650037 Free PMC article.
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).
Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, Neuzillet C, Paoletti X, Bouché O, Aldabbagh K, Michel P, Debieuvre D, Canellas A, Wislez M, Laurent L, Mabro M, Colle R, Hardy-Bessard AC, Mansi L, Colomba E, Bourhis J, Gorphe P, Pointreau Y, Idbaih A, Ursu R, Di Stefano AL, Zalcman G, Aparicio T; GCO-002 CACOVID-19 collaborators/investigators. Lièvre A, et al. Eur J Cancer. 2020 Dec;141:62-81. doi: 10.1016/j.ejca.2020.09.035. Epub 2020 Oct 8. Eur J Cancer. 2020. PMID: 33129039 Free PMC article.
Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma.
Thiery-Vuillemin A, Mouillet G, Nguyen Tan Hon T, Montcuquet P, Maurina T, Almotlak H, Stein U, Montange D, Foubert A, Nerich V, Pivot X, Royer B. Thiery-Vuillemin A, et al. Among authors: almotlak h. Cancer Chemother Pharmacol. 2014 May;73(5):999-1007. doi: 10.1007/s00280-014-2435-7. Epub 2014 Mar 30. Cancer Chemother Pharmacol. 2014. PMID: 24682543
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Stouvenot M, Meurisse A, Saint A, Buecher B, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Smith D, Ghiringhelli F, Parzy A, de la Fouchardiere C, Almotlak H, Vienot A, Jacquin M, Taieb J, Nguyen T, Vernerey D, Borg C, Kim S. Stouvenot M, et al. Among authors: almotlak h. Eur J Cancer. 2022 Feb;162:138-147. doi: 10.1016/j.ejca.2021.11.019. Epub 2022 Jan 4. Eur J Cancer. 2022. PMID: 34995900
20 results